Patients expressing atypical BCR::ABL1 fusions (2% of CML patients) should ideally be monitored by personalized RT-qPCR and results expressed as individual molecular responses compared to baseline levels [37] or by RT-ddPCR assays [38]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.